Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles–mumps–rubella–varicella vaccine: Post-hoc exploratory analysis of results from a matched-cohort study. Issue 39 (18th September 2018)

• Record Type: Journal Article
• Authors: Gvozdenovic, Emilia; Vetter, Volker; Willame, Corinne; Rosillon, Dominique
• Is Part Of: Vaccine. Volume 36:Issue 39(2018)
• Page Start: 5803
• Page End: 5806
• Publication Date: 2018-09-18
• Subjects: MMRV -- Febrile convulsions -- MMR -- Varicella vaccine -- Risk difference; FC febrile convulsions -- MMR trivalent measles-mumps-rubella vaccine -- MMRV tetravalent measles-mumps-rubella-varicella vaccine -- V varicella vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.08.018
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: This post-hoc analysis of data from a matched cohort study investigated the risk of febrile convulsions (FC) 5–12 days post-first dose of measles-mumps-rubella-varicella vaccine (MMRV) in a low-risk population, compared to measles-mumps-rubella (MMR) and varicella (V) vaccines administered separately. The low-risk population excluded children with personal history of FC (Scenario 1) and children with personal or/and family history (≥1 parent/sibling) of FC (Scenario 2). Incidence of FC post-MMRV in Scenario 2 (excluding at risk children) (36.3–49.5/100, 000) and post-MMR+V in the whole cohort including children with personal/family history of FC (43.6/100, 000) were similar. The risk difference of FC increased by 0.2 case/100, 000 in Scenario 1 and decreased by 5.3–8.6 cases/100, 000 of vaccinated children in Scenario 2, compared to the whole cohort. The overall risk of FC post-first dose MMRV vaccination could be lowered by administering MMRV only to children with no personal or family history of FC.